The ET market is growing through diagnostic advances and novel therapeutic development. Key players like Novartis, Incyte, and PharmaEssentia are introducing innovative JAK inhibitors and targeted therapies that improve platelet management and reduce complication risks. Evolving treatment protocols and molecular testing are enabling more personalized care for this chronic blood disorder.
View Full Report:
https://shorturl.at/QyAgR
Gefällt mir
Kommentar
Teilen
